chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Taste disorder
Clinical narrative: Weird taste; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 28Mar2021 at 13:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient medical history included borderline cholesterol. The patient had no known allergies to medications, food, or other products. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and cod-liver oil (MANUFACTURER UNKNOWN); all from an unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021, the patient had a weird taste in mouth, especially when drinking liquids. It had been 7 days already and still he had it. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of weird taste was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Oropharyngeal pain, Pyrexia
Clinical narrative: Sore throat; Head ache; Muscle ache; Fever; Tiredness; This is a spontaneous report from a contactable other healthcare professional, the patient. A 29-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 09:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine and high blood pressure. The patient had no known allergies to medications, food or other products. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) and nifedipine (MANUFACTURER UNKNOWN); all from an unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot Number: EN6208) via an unspecified route of administration in the left arm on 11Mar2021 at 15:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 15:00, the patient experienced head ache, muscle ache, fever, tiredness and sore throat. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of head ache, muscle ache, fever, tiredness and sore throat were recovering.   No follow-up attempts are needed. No further information is expected.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Muscular weakness, Ultrasound Doppler
Clinical narrative: Weakness of legs; This is a spontaneous report from a contactable consumer, the patient. A 78-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6199) via an unspecified route of administration in the right arm on 13Mar2021 at 13:00 (at the age of 78-years-old) as a single dose for COVID-19 immunisation. It was reported that the patient had relevant medical history and was taking concomitant medications within 2 weeks of vaccination, both were unspecified. The patient had no allergies to medications, food, or other products. The patient previously took the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the left arm on 20Feb2021 (at the age of 78-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Mar2021, the patient experienced weakness of legs which got lot worse. The event resulted in doctor or other healthcare professional office/clinic visit. On an unknown date, the patient underwent Doppler study and the result was unknown. The clinical outcome of the event weakness of legs was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Diarrhoea, Fatigue, Headache, Hot flush
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 30Mar2021 at 14:00 (at the age of 32-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have a history of allergies to medications, food, or other products. Concomitant medications included bupropion hydrochloride (BUPROPION HCL XL). The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021, after 3 days of vaccination, the patient experienced headache, diarrhea, abdominal cramping, hot flashes, and fatigue without fever which had lasted 4 days so far and had not gotten better. Adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events experienced headache, diarrhea, abdominal cramping, hot flashes, and fatigue was not resolved at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness, Trismus
Clinical narrative: Strange tightness on jaw; Couldnt close or bite down completely; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 03Apr2021 at 09:15 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus. Concomitant medications included metformin (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN), glipizide (MANUFACTURER UNKNOWN) and atorvastatin (MANUFACTURER UNKNOWN); all for unknown indications and from an unknown date. The patient had no known allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in the left arm on 13Mar2021 at 11:15 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccination within 4 weeks prior to the COVID vaccine.  On 04Apr2021 at 06:00, the patient had tightness on jaw, could not close or bite down completely. This seemed to dissipate the more as the patient moved the jaw, talked and drank fluids. However, it reappeared the next morning and did not go away like the day before. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event tightness on jaw and jaw movements disturbance was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Malaise, Myalgia
Clinical narrative: Pain at injection site; Chills; Headache; Nausea; Loose stools; Muscle pain and aches; Feeling unwell; Rigors; This is a spontaneous report from a contactable nurse, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on 02Apr2021 at 09:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included LVH (left ventricular hypertrophy) and COVID-19 on unknown date. Concomitant medications included acebutolol hydrochloride (SECTRAL) 400mg twice a day and ranolazine (RANEXA); both from unknown dates for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 03:00, the patient experienced pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell and included treatment with tylenol (MANUFACTURER UNKNOWN), ZOFRAN and ibuprofen (MANUFACTURER UNKNOWN). The clinical outcome of the events pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination site pain
Clinical narrative: Pain at injection site; Chills; Headache; Nausea; Loose stools; Muscle pain and aches; Feeling unwell; Rigors; This is a spontaneous report from a contactable nurse, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on 02Apr2021 at 09:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included LVH (left ventricular hypertrophy) and COVID-19 on unknown date. Concomitant medications included acebutolol hydrochloride (SECTRAL) 400mg twice a day and ranolazine (RANEXA); both from unknown dates for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 03:00, the patient experienced pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell and included treatment with tylenol (MANUFACTURER UNKNOWN), ZOFRAN and ibuprofen (MANUFACTURER UNKNOWN). The clinical outcome of the events pain at injection site, chills, rigors, headache, nausea, loose stools, muscle pain and aches and felt unwell was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Chills, Decreased appetite, Fatigue
Clinical narrative: Higher heart rate; loss of appetite; Burning of skin all over; Fatigue; Joint pain; Headache; Injection site pain; Fever; Chills; Muscle pain; Feeling unwell; Lymph node swelling; This is a spontaneous report from a contactable nurse, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 14Mar2021 at 14:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included PASC (Post-acute Sequelae of COVID-19). Patient had no allergies to medications, food, or other products. Concomitant medications included celecoxib (CELEBREX) 200mg for 2 times a day and salbutamol (ALBUTEROL INHALER) as needed, both from unknown dates for unknown indications. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 29Mar2021, the patient underwent SARS-CoV-2 (nasal swab) and the result was negative. On 15Mar2021 at 00:00, the patient experienced joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite and higher heart rate. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. . The clinical outcome of the events of joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite, higher heart rate was recovered with sequelae on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Heart rate increased, Lymphadenopathy, Malaise, Myalgia
Clinical narrative: Higher heart rate; loss of appetite; Burning of skin all over; Fatigue; Joint pain; Headache; Injection site pain; Fever; Chills; Muscle pain; Feeling unwell; Lymph node swelling; This is a spontaneous report from a contactable nurse, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 14Mar2021 at 14:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included PASC (Post-acute Sequelae of COVID-19). Patient had no allergies to medications, food, or other products. Concomitant medications included celecoxib (CELEBREX) 200mg for 2 times a day and salbutamol (ALBUTEROL INHALER) as needed, both from unknown dates for unknown indications. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 29Mar2021, the patient underwent SARS-CoV-2 (nasal swab) and the result was negative. On 15Mar2021 at 00:00, the patient experienced joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite and higher heart rate. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. . The clinical outcome of the events of joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite, higher heart rate was recovered with sequelae on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: Higher heart rate; loss of appetite; Burning of skin all over; Fatigue; Joint pain; Headache; Injection site pain; Fever; Chills; Muscle pain; Feeling unwell; Lymph node swelling; This is a spontaneous report from a contactable nurse, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 14Mar2021 at 14:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included PASC (Post-acute Sequelae of COVID-19). Patient had no allergies to medications, food, or other products. Concomitant medications included celecoxib (CELEBREX) 200mg for 2 times a day and salbutamol (ALBUTEROL INHALER) as needed, both from unknown dates for unknown indications. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 29Mar2021, the patient underwent SARS-CoV-2 (nasal swab) and the result was negative. On 15Mar2021 at 00:00, the patient experienced joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite and higher heart rate. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. . The clinical outcome of the events of joint pain, fatigue, burning of skin all over, headache, injection site pain, fever, chills, muscle pain, feeling unwell, lymph node swelling, loss of appetite, higher heart rate was recovered with sequelae on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Chillblains, Pain, Paraesthesia, Sensory loss
Clinical narrative: Tingling; Loss of sensation; Pain; Distal chilblains on two right toes; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm left on 28Mar2021 at 00:15(at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, asthma, anemia, epstein-barr viremia, depression, migraine, migraine, chronic pain and sulfonamide allergy. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN), cetirizine (MANUFACTURER UNKNOWN), iron (MANUFACTURER UNKNOWN), desvenlafaxine (MANUFACTURER UNKNOWN)and vitamin d nos (MANUFACTURER UNKNOWN) all from unknown date and unknown indication. The patient previously took Amoxicillin and Azithromycin a experienced allergy. Prior to the vaccination, the patient  was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 the patient experienced Tingling, Loss of sensation, Pain and Distal chilblains on two right toes. The patient did not receive any treatment for the event. The clinical outcome of the event Tingling was not resolved. The clinical outcome of the event Loss of sensation was not resolved. The clinical outcome of the event Pain was not resolved. The clinical outcome of the event Distal chilblains on two right toes was not resolved.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Headache, Lymph node pain, Malaise, Nausea
Clinical narrative: unspecified route of administration in the left arm on 03Apr2021 at 14:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included fruit allergy (apples and avocado). Concomitant medications included duloxetine (MANUFACTURER UNKNOWN) from unspecified date. The patient previously received ampicillin (MANUFACTURER UNKNOWN) and clindamycin (MANUFACTURER UNKNOWN) both started on unknown dates for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, 30 minutes after vaccination, the patient experienced headache and nausea. On 04Apr2021, 12 hours after vaccination, the patient experienced sore lymph node in left armpit. On 04Apr2021, 16 hours after vaccination, the patient had lab test of body temperature and found slightly elevated and also experienced aches and pains and malaise. On 05Apr2021, 36 hours after vaccination, the patient experienced sore lymph node in right armpit. After 48 hours of vaccination the patient still experienced symptoms and had to leave work due to nausea. The patient did not receive any treatment for the reported adverse events. The clinical outcome of the events headache, nausea, sore lymph node in left armpit, aches and pains, slightly elevated temperature, malaise and sore lymph node in right armpit was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: unspecified route of administration in the left arm on 03Apr2021 at 14:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included fruit allergy (apples and avocado). Concomitant medications included duloxetine (MANUFACTURER UNKNOWN) from unspecified date. The patient previously received ampicillin (MANUFACTURER UNKNOWN) and clindamycin (MANUFACTURER UNKNOWN) both started on unknown dates for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, 30 minutes after vaccination, the patient experienced headache and nausea. On 04Apr2021, 12 hours after vaccination, the patient experienced sore lymph node in left armpit. On 04Apr2021, 16 hours after vaccination, the patient had lab test of body temperature and found slightly elevated and also experienced aches and pains and malaise. On 05Apr2021, 36 hours after vaccination, the patient experienced sore lymph node in right armpit. After 48 hours of vaccination the patient still experienced symptoms and had to leave work due to nausea. The patient did not receive any treatment for the reported adverse events. The clinical outcome of the events headache, nausea, sore lymph node in left armpit, aches and pains, slightly elevated temperature, malaise and sore lymph node in right armpit was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Nausea
Clinical narrative: Severe dizziness; nausea; severe headache; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 31Mar2021 at 16:45 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included thyroid disorder and latex allergy since an unknown date. The patient received unspecified medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 17:30, the patient experienced severe dizziness, nausea and severe headache. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. Patient did not receive any treatment for the events. The clinical outcome of the events severe dizziness, nausea and severe headache were recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 30Mar2021 at 15:15 (at the age of 38-year-old) as a single dose (0.3 mL) for COVID-19 immunisation. The medical history was reported as none. Concomitant medications included cetirizine hydrochloride (ZYRTEC) 10 mg started on an unknown date for allergy and norethisterone acetate and ethinylestradiol (HAILEY 1.5/30) on unknown date for birth control. The patient had minor skin allergies to some soaps, lotions and detergents. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the patient experienced dizzy and lightheaded in the evening. On 04Apr2021, in the morning and during 1.5 hour drive the patient experienced nauseous that continued on the day and worsened while reaching home. On 05Apr2021, the patient experienced no longer nauseous but still a little dizzy. The patient did not receive any treatment for the event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care The clinical outcome of the events dizzy, light headed was not recovered and that of nausea was recovered on 05Apr2021. No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: Swelling on both cheeks below eyes.; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 02Apr2021 at 09:30 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and potassium low. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), potassium (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), and ascorbic acid, biotin, retinol, copper, zinc (HAIR SKIN NAILS V). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 03Apr2021 at 06:00, the patient experienced swelling on both cheeks below eyes. Therapeutic measures were taken as a result of adverse event and included treatment with unspecified steroids from unknown date. The clinical outcome of the event swelling on both cheeks below eyes was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Muscular weakness, Vaccination site pain
Clinical narrative: Slight pain and weakness in left arm injection site 12 days post injection; Slight pain and weakness in left arm injection site 12 days post injection; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Mar2021 at 13:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to food, medications, or other products  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced slight pain and weakness in left arm injection site 12 days post injection. The patient did not receive any treatment for the adverse events. The adverse events did not result in  doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events slight pain and weakness in left arm injection site 12 days post injection was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose, Blood glucose increased, Haemoglobin
Clinical narrative: Elevated fasting blood glucose levels; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6205) in the left arm on 12Mar2021 at 12:15 (at the age of 64-year-old) as a single dose and received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8735) in the left arm on 02Apr2021 at 12:15 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included elevated blood glucose levels, but under control with diet and exercise, A1C was 5.6. The patient had no known allergies. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other medications or vaccines within four weeks prior to the vaccination. On 12Mar2021 at 17:30 hours, the patient experienced elevated fasting blood glucose levels. The patient had noticed elevated fasting blood glucose levels after the first shot. During the 3 weeks between shots, his fasting blood glucose (BG) readings were 100 or greater all but once. Many readings were well above 100 (as high as 115). He had been carefully regulating his carbs for the last year and he kept track of everything he eats, so these were unusual. After the 2nd shot, his blood glucose reading was unusually high after his first meal, but his fasting readings had been back to nearly normal (100 - 101). The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event elevated fasting blood glucose levels was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous
Clinical narrative: recurrent flat erythematous rash; This is a spontaneous report from a contactable healthcare professional. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date in Feb2021 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously took BACTRIM, CLINDA, LEVAQUIN and penicillin, all for unknown indications from unknown dates and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Feb2021, the patient experienced recurrent flat erythematous rash. Therapeutic measures were taken for the event and included treatment with benadryl on an unknown date. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event of erythematous rash were recovering at the time of report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Insomnia
Clinical narrative: EXTREME insomnia/COULD NOT SLEEP. I was waking up every 30 minutes. All night.; was absolutely exhausted; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 15:45 (at the age of 25-years-old), as a single dose for COVID-19 immunisation. The patient's medical history was reported as several. The patient received several unspecified concomitant medications for unspecified indications on unknown dates. The patient had many unspecified allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04Apr2021 at 22:30, the worst side effect the patient experienced was extreme insomnia. The patient was absolutely exhausted, took all of her medicines, including muscle relaxers and high dose gabapentin and could not sleep. The patient was waking up every 30 minutes, all night. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the reported events and included all the patient's medicines, including muscle relaxers and high dose gabapentin. The clinical outcome of the events extreme insomnia and absolutely exhausted was recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site rash, Vaccination site warmth
Clinical narrative: a small rash at the vaccine site; a small rash at the vaccine site. It was warm, red, itchy, sore to the touch.; a small rash at the vaccine site. It was warm, red, itchy, sore to the touch.; a small rash at the vaccine site. It was warm, red, itchy, sore to the touch.; a small rash at the vaccine site. It was warm, red, itchy, sore to the touch.; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot Number: EP6955) via an unspecified route of administration in the left arm on 18Mar2021 at 19:15(at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, shellfish allergy,  pollen allergy, heart arrhythmia, atrial fibrillation and fatty liver. The patient received unspecified medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 20:30 the patient experienced a small rash at the vaccine site approximately 3 inches across and about 1 inch down. It was warm, red, itchy, sore to the touch. It was also firm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment herself with Benadryl ointment. The clinical outcome of the event a small rash at the vaccine site, It was warm, red, itchy, sore to the touch was recovered on 25Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Severe headache; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 22Mar2021 at 11:30 (at the age of 62-year-old), as a single dose for COVID-19 immunisation. Patient had no medical history. The patient had no known allergies to medications, food or other products. Concomitant medications included levothyroxine 150 mcg (MANUFACTURER UNKNOWN), colchicine 0.6mg (MANUFACTURER UNKNOWN) and sertraline (MANUFACTURER UNKNOWN) all for unknown indication from an unknown date. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 10:00, the patient experienced severe headache four days after first vaccine. The event resulted in doctor or other healthcare professional office or clinic visit. Therapeutic measures were taken as a result of severe headache and included treatment with ibuprofen 600mg (MANUFACTURER UNKNOWN). The clinical outcome of the event severe headache was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Lymphadenopathy
Clinical narrative: Fatigue; Joint pain; Swollen lymph node on the right side of the face; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the arm left on 30Mar2021 at 09:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as many. The patient had received many medications (unspecified) within 2 weeks prior to the vaccination. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the arm left on 09Mar2021 at 09:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced fatigue, joint pain and a swollen lymph node on the right side of the face. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events fatigue, joint pain and swollen lymph node on the right side of the face was resolving.  No follow-up attempts are needed. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hypoaesthesia, Paraesthesia, Swelling face
Clinical narrative: Face had numb feeling; Face tingly feeling; Chills; Slight swollen feeling in upper cheek; This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: E130) via an unspecified route of administration in the right arm on 04Apr2021 at 13:00 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 18:30 the patient experienced that her face had a numb feeling in both of her upper cheeks. She could still feel her face but had numb/tingly feeling. Developed chills and numbness when away. The patient took Advil and chills went away but face numbness returned but not as prominent and more scattered. She reported she feels mostly better this morning just slight swollen feeling in upper cheek on right side occasionally but face looks normal. Therapeutic measures were taken as a result of events and included treatment with Advil. The adverse events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. The clinical outcome of the event face had numb feeling, face tingly feeling, chills and slight swollen feeling in upper cheek was recovering at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Fatigue, Headache, Nausea
Clinical narrative: No interest in food; Tiredness; Chills; Nausea; Headache; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 02Apr2021 at 14:30 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Medical history included lupus, thyroidectomy, atrial fibrillation (Afib), obese, high blood pressure (HBP) and arthritis. The patient previously received penicillin for an unknown indication on an unknown date and experienced allergy. Concomitant medications included diltiazem (MANUFACTURER UNKNOWN), apixaban (ELIQUIS), metoprolol (MANUFACTURER UNKNOWN), levothyroxine (L-THYROXINE) and omeprazole (MANUFACTURER UNKNOWN), all from an unknown date for unknown indication and unknown if ongoing. The patient previously took the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 12Mar2021 at 15:00 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 07:00, the patient experienced tiredness, chills, nausea, headache and appetite lost. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events of fatigue, chills, nausea, headache and appetite lost was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache, Nasal congestion, Nausea, Neck pain
Clinical narrative: Soreness in body; Congestion in nose; Congestion in throat; Nausea; Itching in random spots on body; Headache; just overall felt terrible.; Soreness in neck area; Soreness in injection arm; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 01Apr2021 at 10:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included Localized epidermolyisis bullosa simplex from an unspecified date. Concomitant medications included terbinafine (LAMISIL), ascorbic acid; biotin; calcium pantothenate; cyanocobalamin; ergocalciferol; iron; nicotinamide; pyridoxine hydrochloride; retinol; riboflavin; thiamine hydrochloride; tocopheryl acetate (CENTRUM) all from an unknown date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 the patient experienced soreness in injection arm, side and neck area. On 02Apr2021 the patient experienced a headache and nausea and just overall felt terrible. Over the next few days, soreness in body, congestion in nose and throat, and itching in random spots on body. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Clinical outcome of neck pain, general body pain, nose congestion, throat constriction, nausea, painful arm, itching, headache, feeling miserable was resolving at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Pruritus, Throat tightness
Clinical narrative: Soreness in body; Congestion in nose; Congestion in throat; Nausea; Itching in random spots on body; Headache; just overall felt terrible.; Soreness in neck area; Soreness in injection arm; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 01Apr2021 at 10:45 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included Localized epidermolyisis bullosa simplex from an unspecified date. Concomitant medications included terbinafine (LAMISIL), ascorbic acid; biotin; calcium pantothenate; cyanocobalamin; ergocalciferol; iron; nicotinamide; pyridoxine hydrochloride; retinol; riboflavin; thiamine hydrochloride; tocopheryl acetate (CENTRUM) all from an unknown date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 the patient experienced soreness in injection arm, side and neck area. On 02Apr2021 the patient experienced a headache and nausea and just overall felt terrible. Over the next few days, soreness in body, congestion in nose and throat, and itching in random spots on body. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Clinical outcome of neck pain, general body pain, nose congestion, throat constriction, nausea, painful arm, itching, headache, feeling miserable was resolving at the time of reporting.  No follow-up attempts are needed. No further information is expected.